An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
Latest Information Update: 13 Aug 2026
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Renal cell carcinoma; Transitional cell carcinoma
- Focus Therapeutic Use
- Acronyms RAMPART
Most Recent Events
- 30 May 2026 According to a ICR media release, data from this were presented at the 2026 American Society of Clinical Oncology (ASCO).
- 03 Sep 2020 Planned End Date changed from 1 Dec 2037 to 1 Dec 2034.
- 03 Sep 2020 Planned primary completion date changed from 1 Dec 2023 to 1 Jul 2024.